On May 31, 2022, Robin, J. B.; Theron, A.; Quittet, P.; Exbrayat, C.; Gaillard, J. B.; Lavabre-Bertrand, T.; David, S.; Saad, A.; Jourdan, E.; Cartron, G. published an article.Application of 380843-75-4 The title of the article was Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in East Occitania. And the article contained the following:
Tyrosine kinase inhibitor (TKI) discontinuation in chronic phase chronic myeloid leukemia (CML) patients has been examined in a real-life setting in the east occitania region of France. We have collected sex, age, prognostic scores, pre-TKI treatment, TKI length and response, relapse data from patients who had stopped TKI in prolonged complete mol. remission (CMR), and analyzed relapse risk factors. Sixty consecutive patients were included from Jan. 2010 to Dec. 2016. Sixteen received pre-TKI treatment. Fifty-three received a first-generation TKI, and seven had a second-generation TKI in first-line therapy. The median TKI time to achieve CMR was 20.5 mo [5-137]. The median TKI length before discontinuation treatment was 73 mo [12-158]. Twenty-two patients (37%) relapsed with a median time to relapse of 6 mo [3-27]. An intermediate or high Sokal score was the only relapse risk factor (HR = 3.32, p < 0.05) associated with relapse after TKI discontinuation. TKI discontinuation was possible without relapse for half of the patients in chronic phase CML. In a real-life cohort, a high-risk Sokal score at diagnosis appears to be an adverse prognosis feature for TKI discontinuation. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Application of 380843-75-4
The Article related to chronic myeloid leukemia recurrence tyrosine kinase inhibitor discontinuation france, chronic myeloid leukemia, complete molecular response, molecular recurrence-free remission, tyrosine kinase inhibitor and other aspects.Application of 380843-75-4
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics